Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ADVANZ PHARMA Corp. Limited

https://www.advanzpharma.com/

Latest From ADVANZ PHARMA Corp. Limited

Canary Speech’s Voice AI Can Help Detect Alzheimer’s With 40-Second Conversation

AI voice tech start-up Canary Speech is developing algorithmic models for detecting behavioral health, progressive neurological and cognitive diseases based on a 40-second recording of speech. Medtech Insight caught up with Canary CEO Henry O’Connell at DHIS West to learn more about the company and its plans.

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks Advanced Therapies

Finance Watch: Scion Life Sciences Launches With $310m Inaugural VC Fund

Private Company Edition: Scion’s first fund exceeded its initial $250m fundraising goal. Also, The Column Group’s incubator raised a $400m-plus fund and Seroba’s fourth fund reaches $134m, while Neurona raised a $120m financing and Cour closed a $105m series A round.

Financing Innovation

Rare Disease Drug Govorestat & Odevixibat Resubmission Among New EU Filings

The latest marketing applications under review by the European Medicines Agency include govorestat for classic galactosemia, a condition for which there are no treatments, and odevixibat for Alagille syndrome.

Europe Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • ADVANZ PHARMA
    • ADVANZ PHARMA Corp. Limited
    • Amdipharm Mercury Limited
    • Concordia Healthcare Corp.
    • Concordia International Corp.
    • Concordia Laboratories, Inc.
    • Concordia Pharmaceuticals, Inc.
    • Covis Pharma S.à.r.l, Covis Injectables, S.à.r.l
    • Correvio Pharma Corp
UsernamePublicRestriction

Register